tiprankstipranks
Trending News
More News >
Cooper Companies (COO)
:COO
Advertisement

Cooper Co (COO) AI Stock Analysis

Compare
580 Followers

Top Page

COO

Cooper Co

(NASDAQ:COO)

Rating:65Neutral
Price Target:
$69.00
▲(2.37% Upside)
Cooper Co's strong financial performance and robust free cash flow are significant strengths, providing a solid foundation for future growth. However, the stock's bearish technical indicators and overvaluation present notable risks. The mixed sentiment from the earnings call, with challenges in revenue expectations, further tempers the overall score.
Positive Factors
Growth Potential
Investor meetings with company executives have increased confidence in the company's growth outlook and future earnings potential.
Market Outlook
Investor concerns over the health of the contact lens market appear overblown, with new fittings remaining strong and no evidence of wearers trading down.
Valuation
A perceived gap between the company's valuation and its strong fundamentals presents an attractive opportunity for investors.
Negative Factors
Financial Guidance
Management lowered FY25 revenue guidance, and the new guidance is notably below the Street's expectations.
Sales Performance
CVI sales increased just 2% organic, falling below consensus, given declining Clariti sales and greater than expected weakness in APAC.
Stock Performance
Cooper (COO) shares are down 13% since its FQ2 call and trading at its lowest multiple in nearly 10 years.

Cooper Co (COO) vs. SPDR S&P 500 ETF (SPY)

Cooper Co Business Overview & Revenue Model

Company DescriptionCooper Co (COO) is a diversified company operating primarily in the consumer goods and industrial sectors. The company specializes in manufacturing high-quality products ranging from household items to industrial supplies. With a strong emphasis on sustainability and innovation, COO aims to meet the evolving needs of its customers while maintaining a commitment to environmental responsibility.
How the Company Makes MoneyCooper Co generates revenue through multiple streams, including direct sales of its consumer goods to retailers and distributors, as well as online sales through its e-commerce platform. The company also earns income from B2B contracts, providing industrial supplies and services to various businesses. Additionally, COO has established strategic partnerships with major retailers, which helps enhance its market reach and brand visibility. Seasonal promotions and product launches further contribute to sales spikes, while ongoing investment in research and development ensures the company remains competitive and responsive to market demands.

Cooper Co Key Performance Indicators (KPIs)

Any
Any
Revenue by Geography
Revenue by Geography
Breaks down revenue across different regions, revealing where the company is strongest and where it may face risk or growth potential due to local economic conditions or market share shifts.
Chart InsightsCooper Co's revenue growth in the United States and Europe has been robust, with notable gains in the latest quarters, driven by strong performance in key segments like myopia management and surgical devices. However, the earnings call highlights potential risks, including tariff impacts and fertility market softness, which could temper future growth. Despite these challenges, the company remains optimistic, adjusting its revenue guidance upward for 2025, reflecting confidence in its strategic initiatives and market positioning.
Data provided by:Main Street Data

Cooper Co Earnings Call Summary

Earnings Call Date:Aug 27, 2025
(Q3-2025)
|
% Change Since: |
Next Earnings Date:Dec 04, 2025
Earnings Call Sentiment Neutral
The earnings call demonstrated robust free cash flow and strong performance in the EMEA region, alongside significant developments in the MyDay product line. However, there were notable challenges with revenue coming in below expectations due to a decline in Clarity orders and weakness in the Asia Pac e-commerce segment. The sentiment is balanced with positive prospects for MyDay and Myopia management but weighed down by immediate revenue challenges.
Q3-2025 Updates
Positive Updates
Strong Free Cash Flow
Free cash flow was robust at $165 million, and the company repurchased $52 million of stock during the quarter.
EMEA Region Performance
EMEA delivered a strong quarter, growing 14% or 6% organically, reinforcing the number one position in the region and becoming CooperVision's largest revenue region globally.
MyDay Product Developments
Several positive developments surrounding the MyDay product family, including resolving manufacturing constraints and renewing large contracts, which offer significant growth opportunities.
Myopia Management Growth
MiSight grew by 23%, led by a record-setting quarter in EMEA. There is confidence in achieving the objective of $100 million in MiSight sales this year.
Negative Updates
Revenue Below Expectations
Q3 consolidated revenues were $1.06 billion, which was below expectations, driven by declines in Clarity orders and weakness in the pure play e-commerce segment in Asia Pac.
Clarity Product Challenges
Clarity orders declined globally, especially in Asia Pac and The Americas, as customers shifted focus to MyDay due to fitting activity.
E-commerce Channel Weakness
Greater than expected weakness in the pure play e-commerce segment in Asia Pac, excluding Japan, with a notable impact in China.
PARAGARD Sales Decline
PARAGARD sales declined by 10% following a strong start to the fiscal year, driven by advanced purchases ahead of a price increase.
Company Guidance
In the recent Q3 2025 earnings call, The Cooper Companies provided guidance indicating a mixed performance with Q3 consolidated revenues rising 5.7% year-over-year to $1.06 billion, but organic growth was just 2%. The company reported a strong non-GAAP earnings increase of 15% to $1.1 billion and a robust free cash flow of $165 million. However, revenues were lower than expected due to a decline in Clarity globally, driven by a shift towards premium daily lenses and challenges in the pure play e-commerce segment in Asia Pacific. Looking ahead, Cooper expects Q4 organic revenue growth of 2% to 4% for both CooperVision and CooperSurgical, with continued headwinds from Clarity and potential upside from MyDay fitting activity. For fiscal 2026, Cooper anticipates sustainable revenue growth, market share gains, and operating margin expansion, with an emphasis on mitigating tariffs and enhancing productivity. Additionally, the company plans to generate approximately $2 billion in free cash flow over the next three fiscal years, focusing on debt reduction and share repurchases.

Cooper Co Financial Statement Overview

Summary
Cooper Co is in a strong financial position, with robust profitability, efficient operational management, and a stable balance sheet. The company maintains a conservative leverage structure, enhancing its financial stability and flexibility. However, revenue growth has moderated.
Income Statement
85
Very Positive
Cooper Co has demonstrated strong revenue growth and profitability. The TTM revenue grew by 2.38% over the previous year. Gross profit margin is robust at 63.44%, and the net profit margin is healthy at 10.39%. EBIT and EBITDA margins are solid, reflecting strong operational efficiency. However, the revenue growth rate has slowed compared to previous periods.
Balance Sheet
78
Positive
The company's balance sheet shows a strong equity position with an equity ratio of 66.76%. The debt-to-equity ratio is manageable at 0.31, indicating prudent leverage. Return on equity has increased to 5.00%, suggesting improved profitability on equity investments. The overall balance sheet reflects stability and financial health, with a focus on maintaining a conservative leverage approach.
Cash Flow
80
Positive
Cooper Co's cash flow from operations is strong, with a stable operating cash flow to net income ratio of 1.84. Free cash flow has grown by 27.01% TTM, indicating effective cash management and the ability to fund operations and investments without relying heavily on external financing. The free cash flow to net income ratio is solid, showcasing efficient conversion of income to cash.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue3.99B3.90B3.59B3.31B2.92B2.43B
Gross Profit2.58B2.60B2.36B2.14B1.96B1.53B
EBITDA1.11B1.07B885.90M908.60M863.70M622.90M
Net Income414.20M392.30M294.20M385.80M2.94B238.40M
Balance Sheet
Total Assets12.41B12.32B11.66B11.49B9.61B6.74B
Cash, Cash Equivalents and Short-Term Investments116.20M107.60M120.90M138.20M95.90M115.90M
Total Debt2.59B2.58B2.57B2.76B1.48B2.06B
Total Liabilities4.13B4.23B4.11B4.32B2.66B2.91B
Stockholders Equity8.29B8.08B7.55B7.17B6.94B3.82B
Cash Flow
Free Cash Flow365.90M288.10M215.00M450.40M524.20M176.20M
Operating Cash Flow762.40M709.30M607.50M692.40M738.60M486.60M
Investing Cash Flow-541.70M-764.60M-449.00M-1.83B-450.30M-364.50M
Financing Cash Flow-221.20M39.20M-173.90M1.19B-311.40M-95.50M

Cooper Co Technical Analysis

Technical Analysis Sentiment
Negative
Last Price67.40
Price Trends
50DMA
72.22
Negative
100DMA
74.79
Negative
200DMA
83.42
Negative
Market Momentum
MACD
-0.63
Positive
RSI
39.21
Neutral
STOCH
43.95
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For COO, the sentiment is Negative. The current price of 67.4 is below the 20-day moving average (MA) of 71.78, below the 50-day MA of 72.22, and below the 200-day MA of 83.42, indicating a bearish trend. The MACD of -0.63 indicates Positive momentum. The RSI at 39.21 is Neutral, neither overbought nor oversold. The STOCH value of 43.95 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for COO.

Cooper Co Risk Analysis

Cooper Co disclosed 40 risk factors in its most recent earnings report. Cooper Co reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Cooper Co Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
78
Outperform
$17.76B36.7717.72%0.34%2.88%-5.50%
75
Outperform
$14.93B27.8511.38%1.28%-17.73%
71
Outperform
$9.18B23.9615.36%1.29%1.51%21.70%
65
Neutral
$13.40B33.185.01%6.35%12.94%
54
Neutral
$12.68B136.07-3.30%2.75%-27.41%67.01%
54
Neutral
$7.59B116.65-20.54%-8.36%-669.36%
51
Neutral
$7.83B-0.18-40.01%2.28%22.68%-1.83%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
COO
Cooper Co
67.40
-38.66
-36.45%
ATR
AptarGroup
139.27
-9.08
-6.12%
BAX
Baxter International
24.69
-12.32
-33.29%
HOLX
Hologic
67.12
-15.04
-18.31%
MASI
Masimo
139.71
25.69
22.53%
WST
West Pharmaceutical Services
246.95
-56.26
-18.55%

Cooper Co Corporate Events

Executive/Board Changes
Cooper Co Appoints Barbara Carbone to Board
Positive
Apr 30, 2025

CooperCompanies announced the appointment of Barbara Carbone as an independent director to its Board of Directors, effective May 1, 2025. Ms. Carbone, who brings nearly four decades of experience, primarily from her tenure at KPMG LLP, will also join the Audit Committee. Her extensive expertise in financial and accounting matters, along with leadership skills, is expected to contribute significantly to the company’s governance and strategic direction.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 29, 2025